全文获取类型
收费全文 | 59946篇 |
免费 | 4141篇 |
国内免费 | 225篇 |
专业分类
耳鼻咽喉 | 709篇 |
儿科学 | 1564篇 |
妇产科学 | 1103篇 |
基础医学 | 7600篇 |
口腔科学 | 973篇 |
临床医学 | 5791篇 |
内科学 | 12361篇 |
皮肤病学 | 720篇 |
神经病学 | 5875篇 |
特种医学 | 1987篇 |
外国民族医学 | 4篇 |
外科学 | 9995篇 |
综合类 | 855篇 |
现状与发展 | 1篇 |
一般理论 | 71篇 |
预防医学 | 5348篇 |
眼科学 | 1209篇 |
药学 | 3661篇 |
中国医学 | 64篇 |
肿瘤学 | 4421篇 |
出版年
2023年 | 223篇 |
2022年 | 446篇 |
2021年 | 1046篇 |
2020年 | 595篇 |
2019年 | 982篇 |
2018年 | 1197篇 |
2017年 | 838篇 |
2016年 | 926篇 |
2015年 | 1038篇 |
2014年 | 1687篇 |
2013年 | 2509篇 |
2012年 | 3693篇 |
2011年 | 4029篇 |
2010年 | 2267篇 |
2009年 | 2089篇 |
2008年 | 3625篇 |
2007年 | 3807篇 |
2006年 | 3777篇 |
2005年 | 3854篇 |
2004年 | 3768篇 |
2003年 | 3441篇 |
2002年 | 3386篇 |
2001年 | 564篇 |
2000年 | 436篇 |
1999年 | 621篇 |
1998年 | 771篇 |
1997年 | 654篇 |
1996年 | 587篇 |
1995年 | 553篇 |
1994年 | 495篇 |
1993年 | 456篇 |
1992年 | 403篇 |
1991年 | 406篇 |
1990年 | 325篇 |
1989年 | 346篇 |
1988年 | 312篇 |
1987年 | 299篇 |
1986年 | 276篇 |
1985年 | 326篇 |
1984年 | 496篇 |
1983年 | 417篇 |
1982年 | 533篇 |
1981年 | 517篇 |
1980年 | 500篇 |
1979年 | 271篇 |
1978年 | 298篇 |
1977年 | 288篇 |
1976年 | 233篇 |
1975年 | 227篇 |
1974年 | 243篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Haiyung Cheng Jules I. Schwartz Charles Lin Raju D. Amin James R. Seibold Kenneth C. Lasseter David L. Ebel Dominick J. Tocco J. Douglas Rogers 《Biopharmaceutics & drug disposition》1994,15(5):409-418
MK-679 (R(?)-3-((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)(3-(dimethylamino)-3-oxopropyl)thio)methyl)thio(propanoic acid) is a potent and specific LTD4-receptor antagonist. The disposition of MK-679 was investigated in a three-way crossover study in 12 healthy males receiving single intravenous doses of 75, 250, and 500 mg of MK-679. A greater than proportional increase in the area under the plasma concentration—time curve of MK-679 was observed with increase in dose. The plasma concentration data for each subject fitted well to the differential equations for a two-compartment model with linear tissue distribution and Michaelis-Menten elimination from the central compartment, indicating that the elimination of MK-679 in humans is saturable. In a previous study, the disposition of MK-679 in humans was also dose-dependent when given together with its S(+)-isomer, L-668,018. Thus, the disposition of MK-679 in humans is dose-dependent regardless of the presence of its stereoisomer. Also, the bioavailability of MK-679 was determined in six healthy males receiving simultaneously an oral dose of 250 mg of MK-679 and intravenous infusion of 1 mg 14C-MK-679. Results of this study indicate that the oral bioavailability of MK-679 is nearly quantitative. 相似文献
52.
Enza-Maria Valente Anjum Misbahuddin Francesco Brancati Mark R Placzek Barbara Garavaglia Sergio Salvi Andrea Nemeth Charles Shaw-Smith Nardo Nardocci Anna-Rita Bentivoglio Alfredo Berardelli Roberto Eleopra Bruno Dallapiccola Thomas T Warner 《Movement disorders》2003,18(9):1047-1051
The epsilon-sarcoglycan gene (SGCE) on human chromosome 7q21 has been reported to be a major locus for inherited myoclonus-dystonia. Linkage to the SGCE locus has been detected in the majority of families tested, and mutations in the coding region have been found recently in families with autosomal dominant myoclonus-dystonia. To evaluate the relevance of SGCE in myoclonus-dystonia, we sequenced the entire coding region of the epsilon-sarcoglycan gene in 16 patients with either sporadic or familial myoclonus-dystonia. No mutations were found. This study suggests that epsilon-sarcoglycan does not play an important role in sporadic myoclonus-dystonia and supports genetic heterogeneity in familial cases. 相似文献
53.
Dr. Andrew G. Bostom M.D. Dr. Anne L. Hume Pharm.D. Dr. Charles B. Eaton M.D. Dr. Joseph P. Laurino Ph.D. Ms. Lisa R. Yanek B.A. Ms. Mary S. Regan B.S. Mr. William H. McQuade M.P.H. Dr. Wendy Y. Craig Ph.D. Ms. Gayle Perrone M.B.A. Dr. Paul F. Jacques Sc.D. 《Pharmacotherapy》1995,15(4):458-464
Study Objective . To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design . Randomized, double-blind, placebo-controlled trial. Setting . Outpatient clinic. Patients . Forty-four patients with documented premature CHD. defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions . Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results . High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p<0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p=0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. Conclusions . Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD. 相似文献
54.
Juan C. Kupferman Charles L. Stewart Frederick J. Kaskel Richard N. Fine 《Pediatric nephrology (Berlin, Germany)》1996,10(2):143-146
Renal and urological anomalies in Down syndrome (DS) have received little attention compared with the nephrourological findings described in other chromosomal abnormalities. Renal hypoplasia, hydroureteronephrosis, ureterovesical and ureteropelvic junction obstruction, and vesicoureteral reflux, but not posterior urethral valves, have been associated with DS. We report the occurrence of posterior urethral valves in three male infants with DS at a single institution. All had multiple urological procedures for correction or palliation of obstruction. Children with DS may have an increased risk for developing posterior urethral valves and obstructive uropathy. Furthermore, they may also develop chronic renal failure secondary to posterior urethral valves. Therefore, we suggests that infants with DS be screened with ultrasonography for renal and urological abnormalities early in life and, if abnormal, a contrast voiding cystourethrogram be performed to rule out posterior urethral valves or other bladder or urethral abnormalities. A review of the renal and urological anomalies in DS reported in the literature since 1960 is presented. 相似文献
55.
Charles D. Hepler 《International journal of clinical pharmacy》1996,18(6):233-235
Drug-treatment failures can be prevented by applying a Pharmaceutical Care system. Therapeutic outcome monitoring is such a system, which can be applied to the (drug)treatment of several diseases like asthma, diabetes and cardiovascular diseases. Pharmaceutical Care is an outcome oriented, cooperative systematic approach to providing drug therapy directed at the improvement of all dimensions of health related quality of life. 相似文献
56.
Body pain and treatment response in late-life depression. 总被引:2,自引:0,他引:2
Jordan F Karp Debra Weiner Karen Seligman Meryl Butters Mark Miller Ellen Frank Jacqueline Stack Benoit H Mulsant Bruce Pollock Mary Amanda Dew David J Kupfer Charles F Reynolds 《The American journal of geriatric psychiatry》2005,13(3):188-194
OBJECTIVE: The authors investigated the influence of body pain on 1) time to treatment response and 2) suicidal ideation, in late-life depression. They hypothesized that higher levels of body pain would predict a longer time to and lower likelihood of response, and increased levels of suicidal ideation. METHODS: Subjects (N=187) were older adult outpatients (age > or =69 years), with current episodes of major depression, who were openly treated with paroxetine up to 40 mg daily and weekly interpersonal psychotherapy. Response was defined as 3 consecutive weeks of Hamilton Rating Scale for Depression at < or =10. Body pain was measured with the Bodily Pain Index of the SF-36 quality-of-life assessment. Authors used survival-analysis models on the responder sample to test the effect of body pain on response, after controlling for severity of depression. RESULTS: Overall response rate was 75.4%. Nonresponders reported more severe pain at baseline. After covarying for severity of baseline depression, no effect was found for physical pain on time-to-response or degree of suicidality. Bodily pain remained stable during acute treatment for responders, independent of depression response to combination psychotherapy and antidepressant treatment. CONCLUSIONS: Older adult patients with higher levels of physical pain can still respond to antidepressant treatment; however, reported bodily pain may be associated with a more difficult-to-treat depression. 相似文献
57.
Andrew R. Hoellein MD Christopher A. Feddock MD Charles H. Griffith III MD MSPH John F. Wilson PhD Donald R. Barnett MD MSPH Pat F. Bass III MD MS T. Shawn Caudill MD MSPH 《Journal of general internal medicine》2004,19(5P2):562-565
Due to recent public debate and newly imposed resident work hour restrictions, we decided to investigate the relationship of resident call status to their ambulatory patients' satisfaction. Resident continuity clinic patients were asked to rate their level of satisfaction on a 10-point Likert-type scale. Using multiple regression approaches, these data were then assessed as a function of resident call status. We found that in 646 patient encounters, patient satisfaction scores were significantly less when the resident was postcall, 8.99 ± 1.8, than when not postcall, 9.31 ± 1.3. We herein discuss etiologies and implications of these findings for both patient care and medical education. 相似文献
58.
59.
It has been proposed that administration of non-nitrogenous precursors to glycine is necessary to realize the full potential of benzoate metabolism as a pathway for disposal of waste nitrogen during ammonia intoxication (Coude et al., Clin Chim Acta 136: 211-217, 1984). However, when glyoxylate, a keto acid precursor to glycine, was administered with benzoate 1 hr prior to a challenge of ammonia, protection against ammonia toxicity was less successful than with benzoate alone. At the cellular and subcellular levels, glyoxylate and benzoate each inhibited the urea cycle in isolated hepatocytes and pyruvate carboxylase in isolated mitochondria. The action of each drug was associated with depletion of aspartate content in isolated hepatocytes and reduction of pyruvate-dependent incorporation of CO2 into aspartate in assays with isolated mitochondria. Depression of aspartate regeneration by inhibition of pyruvate carboxylase is a likely mechanism for impairment of urea cycle activity by both drugs. In whole animals, inhibition of pyruvate carboxylase may contribute to benzoate toxicity and the adverse influence of glyoxylate on benzoate therapy. 相似文献
60.
Charles H Spencer 《Pediatric rheumatology online journal》2007,5(1):21-3
Some pediatric rheumatologists in the West may take for granted that pediatric rheumatology (PR) is a recognized subspecialty.
Yet pediatric rheumatology has been accepted as a subspecialty in the United States only since 1990. There are still countries
where many pediatric subspecialties are not given official recognition and support, including PR. This lack of recognition
delays and impedes the development of PR, appropriate musculoskeletal and rheumatic teaching in medical schools, and optimal
diagnosis and treatment for children with these illnesses. In the opinion of editorial staff, each country where pediatric
rheumatology is reasonably well developed as a subspecialty has an obligation to help our pediatric rheumatologists elsewhere
gain recognition, support, and respect. The Pediatric Rheumatology European Society (PReS) and the Pediatric Rheumatology
International Trial Organization (PRINTO) have been leaders in this effort, but in many countries, pediatric rheumatology
is still not recognized. This editorial offers rationales and justifications for medical and governmental entities accrediting
pediatric rheumatology as a separate subspecialty that may aid in these efforts. 相似文献